Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalba Martignetti

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Oncologist|November 6, 2008
Racism in the chemotherapy infusion unit: a nurse's storyLidia Schapira, Leah Gordon-Rowe, Rosalba Martignetti, et al.
Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Blood|October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationAnita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Oncologist|November 6, 2008
Racism in the chemotherapy infusion unit: a nurse's storyLidia Schapira, Leah Gordon-Rowe, Rosalba Martignetti, et al.
Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2022
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven ApproachLindsey E Roeker, Tatyana A Feldman, Jacob D Soumerai, et al.
Blood|October 22, 2024
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationAnita Kumar, Jacob Soumerai, Jeremy S Abramson, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Blood Advances|June 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKsJacob D Soumerai, Meghan C Thompson, Ahmet Dogan, et al.
Pageof 1